Company Quick10K Filing
Vertex Pharmaceuticals
Closing Price ($) Shares Out (MM) Market Cap ($MM)
$0.00 260 $46,842
10-K 2020-02-13 Annual: 2019-12-31
10-Q 2019-10-31 Quarter: 2019-09-30
10-Q 2019-08-01 Quarter: 2019-06-30
10-Q 2019-05-01 Quarter: 2019-03-31
10-K 2019-02-13 Annual: 2018-12-31
10-Q 2018-10-25 Quarter: 2018-09-30
10-Q 2018-07-26 Quarter: 2018-06-30
10-Q 2018-04-27 Quarter: 2018-03-31
10-K 2018-02-15 Annual: 2017-12-31
10-Q 2017-10-30 Quarter: 2017-09-30
10-Q 2017-07-28 Quarter: 2017-06-30
10-Q 2017-04-28 Quarter: 2017-03-31
10-K 2017-02-23 Annual: 2016-12-31
10-Q 2016-10-31 Quarter: 2016-09-30
10-Q 2016-08-01 Quarter: 2016-06-30
10-Q 2016-05-03 Quarter: 2016-03-31
10-K 2016-02-16 Annual: 2015-12-31
10-Q 2015-10-30 Quarter: 2015-09-30
10-Q 2015-08-04 Quarter: 2015-06-30
10-Q 2015-05-04 Quarter: 2015-03-31
10-K 2015-02-13 Annual: 2014-12-31
10-Q 2014-11-06 Quarter: 2014-09-30
10-Q 2014-07-31 Quarter: 2014-06-30
10-Q 2014-05-05 Quarter: 2014-03-31
10-K 2014-02-11 Annual: 2013-12-31
10-Q 2013-11-07 Quarter: 2013-09-30
10-Q 2013-08-02 Quarter: 2013-06-30
10-Q 2013-05-08 Quarter: 2013-03-31
10-K 2013-03-01 Annual: 2012-12-31
10-Q 2012-11-06 Quarter: 2012-09-30
10-Q 2012-08-08 Quarter: 2012-06-30
10-Q 2012-05-10 Quarter: 2012-03-31
10-K 2012-02-22 Annual: 2011-12-31
10-Q 2011-11-03 Quarter: 2011-09-30
10-Q 2011-08-09 Quarter: 2011-06-30
10-Q 2011-05-06 Quarter: 2011-03-31
10-Q 2010-10-28 Quarter: 2010-09-30
10-Q 2010-08-03 Quarter: 2010-06-30
10-Q 2010-05-03 Quarter: 2010-03-31
10-K 2010-02-19 Annual: 2009-12-31
8-K 2020-01-30 Earnings, Exhibits
8-K 2019-10-30 Earnings, Exhibits
8-K 2019-10-24 Other Events
8-K 2019-09-17 Enter Agreement, Leave Agreement, Off-BS Arrangement, Off-BS Arrangement
8-K 2019-08-30 Enter Agreement
8-K 2019-07-31 Earnings, Exhibits
8-K 2019-07-24 Officers, Exhibits
8-K 2019-06-06 Enter Agreement
8-K 2019-06-05 Officers, Shareholder Vote
8-K 2019-04-30 Earnings, Exhibits
8-K 2019-03-28 Officers
8-K 2019-02-21 Officers
8-K 2019-02-05 Earnings, Exhibits
8-K 2019-01-23 Officers
8-K 2018-12-13 Officers
8-K 2018-10-24 Earnings, Exhibits
8-K 2018-07-25 Earnings, Exhibits
8-K 2018-05-17 Enter Agreement, Shareholder Vote
8-K 2018-04-26 Earnings, Exhibits
8-K 2018-02-12 Regulation FD
8-K 2018-01-31 Earnings, Exhibits

Vertex Pharmaceuticals Financials

VRTX Metrics, Comps, Filings

Annual | Quarterly

Business

We invest in scientific innovation to create transformative medicines for people with serious diseases. Our business is focused on developing and commercializing therapies for the treatment of cystic fibrosis, or CF, and advancing our research and development programs in other diseases.

Our goal is to develop treatment regimens that will provide benefits to all patients with CF and will enhance the benefits that currently are being provided to patients taking our medicines. Our marketed medicines are SYMDEKO/SYMKEVI (tezacaftor in combination with ivacaftor), ORKAMBI (lumacaftor in combination with ivacaftor) and KALYDECO (ivacaftor). These three medicines are collectively approved to treat approximately half of the 75,000 CF patients in North America, Europe and Australia.

We believe the triple combination regimens of next-generation correctors in combination with tezacaftor and ivacaftor that we are evaluating in Phase 3 clinical development could potentially provide benefits to all CF patients who have at least one F508del mutation in their cystic fibrosis transmembrane conductance regulator, or CFTR, gene (approximately 90% of all CF patients). This would provide (i) the first treatment for the underlying cause of CF for patients who have one copy of the F508del mutation in their CFTR gene and a second mutation that results in minimal CFTR function, whom we refer to as F508del/Min patients; and (ii) an improved treatment option for a majority of patients who are currently eligible for our products.


Valuation ($BB)

Market Cap, Enterprise Value

Balance Sheet ($BB)

Assets, Stockholders' Equity

Income Statement ($BB Annual)

Revenue, Gross Profit, Net Income

Cash Flow ($BB Annual)

Operating, Investing, Financing

Comps ($MM TTM) Market Cap Gross Margin EV/EBITDA Ret on Assets Assets Liabilities Revenue G Profit Net Income EBITDA EV
Bristol Myers Squibb (BMY) 82,160 70% 10.6 10% 57,433 39,679 24,173 16,837 5,680 7,151 76,061
Celgene (CELG) 72,111 96% 10.4 14% 41,363 29,276 16,982 16,354 5,880 7,734 80,796
GW Pharmaceuticals (GWPH) 45,954 89% -870.1 -8% 848 128 205 182 -64 -52 45,400
Allergan (AGN) 54,957 63% -241.2 -5% 122,925 38,486 15,818 9,949 -5,872 -316 76,270
Zoetis (ZTS) 60,799 51% 29.1 13% 11,272 8,594 6,150 3,124 1,461 2,252 65,484
Sanofi (SNY) 52,845 0% 111,408 0 0 0 0 52,184
Vertex Pharmaceuticals (VRTX) 43,431 87% 46.7 29% 7,515 2,261 3,620 3,135 2,144 857 40,027
Regeneron Pharmaceuticals (REGN) 32,266 0% 12.2 15% 13,939 3,435 7,622 0 2,144 2,539 30,869
Alexion Pharmaceuticals (ALXN) 23,581 92% 12.8 10% 14,815 4,448 4,736 4,359 1,470 1,874 23,912
Biomarin Pharmaceutical (BMRN) 12,700 79% 1,194.1 -1% 4,558 1,484 1,250 986 -39 11 13,147
Elanco Animal Health (ELAN) 9,964 52% 30.6 1% 8,824 3,336 3,083 1,611 94 393 12,004
Mylan (MYL) 10,768 34% 12.5 -0% 31,054 19,590 8,309 2,810 -4 1,882 23,458
Teva (TEVA) 7,142 43% -10.6 -7% 57,246 42,322 17,455 7,550 -3,961 -2,814 29,713
Sarepta Therapeutics (SRPT) 5,588 0% -7.9 -36% 1,702 707 365 0 -620 -576 4,529
Ionis Pharmaceuticals (IONS) 8,784 76% 17.4 15% 2,895 1,397 821 626 436 491 8,536
Sage Therapeutics (SAGE) 7,414 82% -10.7 -56% 1,204 123 5 4 -670 -670 7,152
Bausch (BHC) 7,760 0% 25.3 -1% 31,667 29,107 8,498 0 -266 1,216 30,774
Alnylam Pharmaceuticals (ALNY) 8,913 80% -9.7 -32% 2,542 935 169 135 -821 -820 7,987
Catalent (CTLT) 7,405 32% 23.8 2% 6,120 3,864 2,631 834 152 421 10,021
Jazz Pharmaceuticals (JAZZ) 7,549 21% 11.2 11% 5,528 2,473 2,056 441 609 762 8,530

Balance Sheet ($MM)2010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-31
Cash2434754895696257151,1841,6652,658
Accounts Receivable131831438676178201281410
Inventory1123014315778112124
PP&E151334341,005716698698789812
Assets1,7252,2042,7592,3192,3352,4992,8973,5466,246
Accounts Payable36751014971756174111
Long-Term Debt
Liabilities1,2211,2391,5259631,2381,4051,5591,5041,811
Stockholders' Equity7879991,3561,0759401,1572,0294,435
Income Statement ($MM)2010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-31
Revenue1439511,3338384881,0001,6842,1653,048
Cost of Revenue410
Gross Profit2,638
R&D6377088069198569961,0481,3251,416
SG&A188401437362305377433496558
Tax01939-28912-3-107-1,487
Net Income-75541-51-688-743-588-84922,087
Cash Flow ($MM)2010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-31
Cash Operating-635144268-52-513-3652368451,270
Cash Investing7212-426-5474269104-438-202
Cash Financing425-12417218149718913368-71